Naturopathic Doctor News and Review

Intravenous Phosphatidylcholine in Severe Refractory Mast Cell Activation Syndrome: A Case Report

Melanie Stein, ND Clinical improvement in treatment-refractory MCAS with normal conventional biomarkers and profound oral ...
European Medical Journal

Antibody Therapy Improves Chronic Spontaneous Urticaria Symptoms

Barzolvolimab improved symptoms in chronic spontaneous urticaria, supporting mast cell targeting as a novel treatment strategy. Read more.
Healio

Chronic spontaneous urticaria response to barzolvolimab persists 24 weeks after treatment

Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as ...
Business Insider

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...